Fact check
“A representative from Gillibrand’s office said the five-year delay is meant to give the FDA time for rulemaking.”
Reasoning
Both excerpts from the ProPublica article on the Clear Labels Act state that a representative from Senator Gillibrand’s office explained the five‑year delay is intended to give the FDA time for rulemaking. This directly confirms the claim.
On confidence: The claim is directly quoted in two independent excerpts from the same ProPublica article, which is a Tier 1 primary source.
Important context
The statement is part of a discussion about the Clear Labels Act and its legislative timeline, indicating the delay is linked to regulatory preparation.
Evidence
Supporting (2)
- Tier 1 — Primary sourceClear Labels Act Stripped of Critical Drug Safety Provisions — ProPublica
medical distributors and the retailers don’t want to make sure that they supply the highest-quality product?” In a joint press release, Scott and Gillibrand praised the bill’s progress in the Senate, calling it a “massive win for consumer…
- Tier 1 — Primary sourceClear Labels Act Stripped of Critical Drug Safety Provisions — ProPublica
health policy at Stanford University who has researched the economic pressures that lead to poor-quality generic drugs. “Why is it that the supply chain, the medical distributors and the retailers don’t want to make sure that they supply…
Limitations
The evidence comes from a single news outlet; while ProPublica is a reputable source, no additional independent confirmation is provided within the supplied documents.
- Last verified:
- Sep 27, 2026, 4:24 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
“A Clear Watering Down”: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate VoteProPublica · Naisha Roy